uploads/2018/08/Long-acting.png

Novo Nordisk’s Long-Acting Insulins: A Performance Overview

By

Updated

Tresiba’s revenue trends

Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018, reflecting an ~11% YoY (year-over-year) growth in local currencies.

In the second fiscal quarter of 2018, Tresiba generated revenues of 2 billion Danish kroner, which included 1.2 billion Danish kroner and 316 million Danish kroner in the US and European markets, respectively. In the second quarter in the AAMEO (Africa, Asia, the Middle East, and Oceania), Japan and Korea, and Latin America, Tresiba generated revenues of 82 million Danish kroner, 199 million Danish kroner, and 106 million Danish kroner, respectively. That reflects 48%, 13%, and 39% YoY growth, respectively, in local currencies.

In the same quarter in the US and European markets, Tresiba fell 17% YoY and grew 27% YoY, respectively, in local currencies.

Article continues below advertisement

Xultophy’s revenue trends

In the first half of 2018, Xultophy generated revenues of 720 million Danish kroner compared to 284 million Danish kroner in the first half of 2017. That a ~165% YoY growth in local currencies.

Novo Nordisk has launched Xultophy in 22 countries. The increase in Xultophy sales in Europe primarily contributed to its revenue growth in the first half of 2018.

Xultophy is a combination of insulin degludec and liraglutide. In June, the European Commission approved the label expansion of Xultophy for the inclusion of the data from the LEADER and DEVOTE clinical trials. Novo Nordisk conducted the LEADER trial to evaluate the long-term effect of liraglutide (Victoza) along with the standard of care compared to a placebo therapy for the treatment of individuals with Type 2 diabetes with a high risk of cardiovascular events. It conducted the DEVOTE trial to confirm the cardiovascular safety of insulin degludec U100 (Tresiba) in individuals with Type 2 diabetes with a high risk of cardiovascular events compared to a placebo therapy.

The updated label of Xultophy is expected to strengthen the drug’s commercialization potential.

Levemir’s revenue trends

In the first quarter of 2018, Levemir generated revenues of 5.8 billion Danish kroner compared to 7.6 billion Danish kroner in the first half of 2017. That’s a ~16% YoY decline in local currencies.

Levemir generated revenues of 3 billion Danish kroner in the second quarter of 2018, reflecting a ~10% YoY decline in local currencies. In the same quarter in the United States, Europe, AAMEO, and China, Levemir reported revenues of 1.9 billion Danish kroner, 522 million Danish kroner, 241 million Danish kroner, and 203 million Danish kroner, respectively. That reflects a ~14% decline, an 11% decline, a ~145% growth, and a ~19% growth, respectively, YoY in local currencies.

In the long-acting insulin market, Novo Nordisk’s long-acting insulins compete with Eli Lilly’s (LLY) Basaglar and Sanofi’s (SNY) Lantus, which generated revenues of $201.8 million and 647 million euros, respectively, in the second quarter of 2018.

Advertisement

More From Market Realist